CRC Outcomes Better When First of Multiple Cancers
The findings came from a retrospective analysis of data from the Surveillance, Epidemiology, and End Results (SEER) database of more than half a million people in the US with primary CRC. They were divided into three groups: Group A, with CRC as their only malignancy; group B, with CRC as the first with one or more subsequent primary malignancies; and group C, with CRC as the second of multiple primary malignancies.
The finding that Group B had the highest 5-year survival of the three groups is novel and surprised the authors, but they have some theories to explain it.
'We potentially thought group A would do the best, seeing as they only had one type of cancer. But what we found…is that [group B] actually had the best survival outcome. It could have something to do with the tumor characteristics at a molecular biological level, or potentially because of increased surveillance from having colorectal cancer first,' first author Anjelli Wignakumar, MD, told Medscape Medical News .
On the other hand, those in group A tended to be younger and to present with more aggressive disease, although they still fared better than did those in group C. 'There are lots of potential explanations,' said Wignakumar, a clinical research fellow in Colorectal Department, Cleveland Clinic, Weston, Florida.
Clinically, the takeaway is for comprehensive screening for other types of cancer in people with primary cancers, and in particular screening for CRC in people with other primary cancers. 'Depending on the patient's family history and other things, increasing that screening hopefully increases our risk of picking up something earlier,' she said.
Of the total 592,063 patients with CRC in SEER from 2000-2020, 71.8% were in group A, 11.9% in group B, and 16.3% in group C. Group B included a higher proportion of men (57.1% vs 51.8% and 53.1% for A and C, respectively; P < .001). Group A was significantly younger at CRC presentation (65.7 years vs 67.3 years and 72.6 years, for B and C, respectively; P < .001).
Those in group A were more likely to have elevated pretreatment tumor marker carcinoembryonic antigen (49.7% vs 43.2% and 46.9%, in B and C, respectively; P < .001) and presented more often with liver metastases (17.5% vs 7.4% and 12.1%, respectively; P < .001) or lung metastases (6.3% vs 2.5% and 4.2%, respectively, P < .001).
Right-sided CRC, which has been associated with worse survival compared to left-sided, was more common in group C (38.6%), while left-sided colonic cancer, associated with better survival, was more common in group B (37.9%). Both were significant compared to the other groups ( P < .001).
Surgical treatment was recommended significantly ( P < .001) more often for group B (20.5%) than for groups A (13.0%) or C (14.3%), while systemic adjuvant therapy was given significantly ( P < .001) more often to those in group A (29.0%) than groups B (27.8%) or C (21.3%).
Compared to group B, overall 5-year mortality hazard ratios were 1.26 for group A, which could be attributed to their more advanced disease, the authors said. Those in group C also had higher 5-year mortality (1.66). Those were both statistically significant, with similar trends for cancer-specific mortality.
Mean 5-year survival was 50.4 months for group B, significantly ( P < .001) longer than the 41.8 months for group A and 39.2 months for group C.
In their discussion in the paper, Wignakumar and colleagues presented a variety of hypotheses about the findings, including that group B might have a distinct immune profile that 'enhances their ability to survive multiple cancers and potentially improve their responsiveness to treatment.'
Alternatively, 'Patients who develop a second primary cancer have already demonstrated resilience, having endured the physical and emotional challenges of their initial cancer treatment. This experience may reflect a stronger baseline health status and the benefits of previous successful interventions, contributing to potentially better survival outcomes compared with those facing cancer for the first time.'
Wignakumar had no disclosures.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
a day ago
- CBS News
Certain type of hormone therapy increases breast cancer risk, study finds
Women using a certain type of hormone therapy to treat menopause symptoms could be at higher risk for breast cancer, according to a new study. The study, published Tuesday in The Lancet Oncology, found that estrogen plus progesterone increases the risk of breast cancer in women under 55 with a uterus, while estrogen alone reduces the risk. Dr. Céline Gounder, CBS News medical contributor and editor-at-large for public health at KFF Health News, told "CBS Mornings" Wednesday the study participants, all under age 55, were divided into two groups — women who still have their uterus and those who do not, since they require different types of treatment. A hysterectomy is the surgical removal of the uterus, which may be done for a number of reasons, including abnormal vaginal bleeding, severe pelvic pain, uterine fibroids, severe endometriosis and certain types of cancer. Approximately 600,000 females get hysterectomies in the U.S. each year, according to the Cleveland Clinic. "For the women who do still have a uterus, you have to give estrogen plus progesterone together. Estrogen alone will cause a thickening of the uterine lining, which can cause a different kind of cancer, what we call endometrial cancer. So you have to give the combination," Gounder said. "In women who no longer have a uterus, you can give estrogen alone." And the difference in treatment mattered. "What they found is estrogen alone reduced the risk of breast cancer," she said. "There seems to be a slight increase in risk in breast cancer if you also took progesterone." This research is a "great example of (how) science evolves," Gounder added. It comes after an early 2000s study called the Women's Health Initiative that focused on older women who may not have started hormone replacement therapy until 10 or so years after going through menopause. The study, which raised safety concerns and led to a longtime public misunderstanding around hormone therapy, has since been found problematic in terms of how it was designed. Now healthcare professionals largely consider the treatment option safe and effective. "The newer research is focused on what actually happens in real life, which is women who go through menopause in their 40s or 50s, (and) start treatment around that age," Gounder said. As with most medications, hormone replacement therapy comes with certain risks for some people. The Mayo Clinic notes it can lead to increased risk of heart disease, stroke, blood clots and some cancers. In other cases, however, it can help reduce risk of cancer, prevent bone loss and reduce menopausal symptoms like hot flashes. As the latest study shows, timing and type of hormone therapy can be crucial to potential outcomes, making it important that people consult their doctor and consider family history and other factors when considering treatment options. Gounder said hormone replacement therapy is the most effective treatment for a lot of perimenopausal symptoms, and added, "You really need to sit down and talk to your doctor (to determine) what is the appropriate thing for you."
Yahoo
2 days ago
- Yahoo
Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD
AUSTIN, Texas, July 01, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced new data that will be presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI) in Barcelona, Spain. These presentations reinforce the strong clinical and economic utility of Signatera™ monitoring across colon and rectal cancers (CRC), as well as new clinical validation data on its tissue-free MRD assay. Signatera in CRC surveillance Data on >3,000 CRC patients will be shared in an oral presentation, concluding that adding Signatera ctDNA* monitoring to the current standard of care in surveillance can better identify patients who are candidates for metastasis-directed therapy (MDT). Results indicated that Signatera-positive patients were up to 20x more likely to receive curative-intent MDT than Signatera-negative patients. By comparison, CEA positivity led to only a 2x increase, with no added value in stage IV. Signatera Genome in rectal cancer An analysis will be presented from the MD Anderson INTERCEPT study (n=31) that used serial Signatera Genome testing in patients with locally advanced rectal cancer after neoadjuvant therapy. Results demonstrated 100% specificity/PPV, with surveillance sensitivity of 100% in the surgical cohort and 88% (7/8) overall. Economic utility of Signatera-guided therapy in adjuvant CRC A budget impact model from BUPA, a multinational health insurance provider with over 60 million customers, will outline a 43% expected reduction in healthcare costs using Signatera-guided adjuvant treatment versus standard of care in stage II-III CRC. "We're excited to present these new findings that continue to support the utility of Natera's products across GI cancers," said Adham Jurdi, M.D., senior medical director of oncology at Natera. "These data highlight our commitment to improving outcomes and driving innovation in MRD detection." Full list of data featuring Natera's technology at ESMO GI: July 4, 16:40-16:50 CET | FPN: 20 | Signatera (Oral Presentation)Presenter: Arvind Dasari, M.D., MSClinical utility of including circulating tumor DNA (ctDNA) monitoring in standard of care (SoC) colorectal cancer (CRC) surveillance July 4, 16:50-17:00 CET | FPN: 30 | Signatera (Oral Presentation)Presenter: Hideaki Bando, of ctDNA Clearance with Disease-Free Survival and Safety and Quality of Life from ctDNA-Directed Therapy: Findings from the ALTAIR Study July 4, 15:30-16:30 CET | FPN: 102P | Signatera (Poster Presentation)Presenter: Christos Mikropoulos, MBBS, MSc, M.D. (Res), MRCP, FRCRDirect cost of healthcare analysis of Signatera ctDNA testing in the adjuvant setting for a hypothetical cohort of stage II and stage III colorectal cancer (CRC) patients: a UK private payer perspective July 4, 15:30-16:30 CET | FPN: 243P | Signatera Genome (Poster Presentation)Presenter: Arvind Dasari, M.D., MSClinical performance of Signatera Genome assay in a sub-cohort of locally advanced rectal cancer (LARC) patients (pts) in the MD Anderson INTERCEPT program July 4, 15:30-16:30 CET | FPN: 93P | Tissue-free MRD (Poster Presentation)Presenter: Yoshiaki Nakamura, M.D., validation of a methylation-based, tissue-free colorectal cancer test for the detection of molecular residual disease by circulating tumor DNA July 4, 15:30-16:30 CET | FPN: 89P | Early Cancer Detection (Poster Presentation)Presenter: John P.Y. Shen, of methylation-based biomarkers to predict metastases, treatment effect, and microsatellite status in colorectal cancer Notes*Circulating tumor DNA About Natera Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at and View source version on Contacts Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@ Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@ Sign in to access your portfolio
Business Wire
2 days ago
- Business Wire
Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced new data that will be presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI) in Barcelona, Spain. These presentations reinforce the strong clinical and economic utility of Signatera™ monitoring across colon and rectal cancers (CRC), as well as new clinical validation data on its tissue-free MRD assay. Signatera in CRC surveillance Data on >3,000 CRC patients will be shared in an oral presentation, concluding that adding Signatera ctDNA * monitoring to the current standard of care in surveillance can better identify patients who are candidates for metastasis-directed therapy (MDT). Results indicated that Signatera-positive patients were up to 20x more likely to receive curative-intent MDT than Signatera-negative patients. By comparison, CEA positivity led to only a 2x increase, with no added value in stage IV. Signatera Genome in rectal cancer An analysis will be presented from the MD Anderson INTERCEPT study (n=31) that used serial Signatera Genome testing in patients with locally advanced rectal cancer after neoadjuvant therapy. Results demonstrated 100% specificity/PPV, with surveillance sensitivity of 100% in the surgical cohort and 88% (7/8) overall. Economic utility of Signatera-guided therapy in adjuvant CRC A budget impact model from BUPA, a multinational health insurance provider with over 60 million customers, will outline a 43% expected reduction in healthcare costs using Signatera-guided adjuvant treatment versus standard of care in stage II-III CRC. 'We're excited to present these new findings that continue to support the utility of Natera's products across GI cancers,' said Adham Jurdi, M.D., senior medical director of oncology at Natera. 'These data highlight our commitment to improving outcomes and driving innovation in MRD detection.' Full list of data featuring Natera's technology at ESMO GI: July 4, 16:40-16:50 CET | FPN: 20 | Signatera (Oral Presentation) Presenter: Arvind Dasari, M.D., MS Clinical utility of including circulating tumor DNA (ctDNA) monitoring in standard of care (SoC) colorectal cancer (CRC) surveillance July 4, 16:50-17:00 CET | FPN: 30 | Signatera (Oral Presentation) Presenter: Hideaki Bando, M.D. Association of ctDNA Clearance with Disease-Free Survival and Safety and Quality of Life from ctDNA-Directed Therapy: Findings from the ALTAIR Study July 4, 15:30-16:30 CET | FPN: 102P | Signatera (Poster Presentation) Presenter: Christos Mikropoulos, MBBS, MSc, M.D. (Res), MRCP, FRCR Direct cost of healthcare analysis of Signatera ctDNA testing in the adjuvant setting for a hypothetical cohort of stage II and stage III colorectal cancer (CRC) patients: a UK private payer perspective July 4, 15:30-16:30 CET | FPN: 243P | Signatera Genome (Poster Presentation) Presenter: Arvind Dasari, M.D., MS Clinical performance of Signatera Genome assay in a sub-cohort of locally advanced rectal cancer (LARC) patients (pts) in the MD Anderson INTERCEPT program July 4, 15:30-16:30 CET | FPN: 93P | Tissue-free MRD (Poster Presentation) Presenter: Yoshiaki Nakamura, M.D., Ph.D. Clinical validation of a methylation-based, tissue-free colorectal cancer test for the detection of molecular residual disease by circulating tumor DNA July 4, 15:30-16:30 CET | FPN: 89P | Early Cancer Detection (Poster Presentation) Presenter: John P.Y. Shen, M.D. Development of methylation-based biomarkers to predict metastases, treatment effect, and microsatellite status in colorectal cancer Notes * Circulating tumor DNA About Natera Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in 'Risk Factors' in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at and
